Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daridorexant - Idorsia Pharmaceuticals

Drug Profile

Daridorexant - Idorsia Pharmaceuticals

Alternative Names: ACT-541468; DORA; Nemorexant - Idorsia Pharmaceuticals

Latest Information Update: 30 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Sleep disorder therapies
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Insomnia
  • Phase I Sleep apnoea syndrome

Most Recent Events

  • 05 Dec 2019 Daridorexant licensed to Mochida Pharmaceutical in Japan
  • 05 Nov 2019 Idorsia Pharmaceuticals completes a phase I trial in Sleep apnoea syndrome in Germany (PO, Tablet) (NCT03765294)
  • 22 Oct 2019 Efficacy and adverse events data from pooled analysis of two phase II trials in Insomnia released by Idorsia Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top